Pituitary Photon Counting Detector CT for Cushing Disease: Pre-operative Lesion Localization, Intraoperative Findings, and Post-operative Outcomes.

Ian T Mark, Giorgos Michalopoulos, Jamie Van Gompel, Maria Peris Celda, Irina Bancos, Diane Donegan, Lucinda M Gruber, Dana Erickson, Alex A Nagelschneider, Lifeng Yu
{"title":"Pituitary Photon Counting Detector CT for Cushing Disease: Pre-operative Lesion Localization, Intraoperative Findings, and Post-operative Outcomes.","authors":"Ian T Mark, Giorgos Michalopoulos, Jamie Van Gompel, Maria Peris Celda, Irina Bancos, Diane Donegan, Lucinda M Gruber, Dana Erickson, Alex A Nagelschneider, Lifeng Yu","doi":"10.3174/ajnr.A8893","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>MRI fails to localize a tumor in up to 40% of cases of ACTH dependent Cushing Disease (CD), impacting patient outcomes and creating uncertainty in the diagnosis. Photon-counting detector CT (PCD-CT) is a new CT technology with better imaging performance than conventional CT. PCD-CT is a novel imaging technique for CD, especially for MR-negative cases, however its application to CD remains unknown.</p><p><strong>Materials and methods: </strong>We present a cohort of consecutive patients with a pre-operative PCD-CT undergoing transsphenoidal surgery for CD at a single institution from September 2023 to January 2025. All patients underwent gadolinium-enhanced pituitary MRI for baseline work-up and PCD-CT as part of their preoperative planning imaging. Both imaging modalities were used to localize the lesion and guide surgical planning. The accuracies of MRI and PCD-CT were based on confirmation of the lesion location by a combination of intraoperative visualization, pathologic confirmation, and postoperative biochemical remission, and were compared with each other via Fisher's exact test.</p><p><strong>Results: </strong>Twenty-five patients with CD were included in this analysis. The cohort's median age was 50 years old, and 88% were female. At diagnosis, 88% had central obesity, 76% had hypertension, 48% had type II diabetes mellitus, and 20% had osteoporosis. Contrast-enhanced MRI accurately identified 56% of lesions, while it was negative in 24% and misleading in 20%. Dynamic contrast-enhanced PCD-CT was superior in localizing CD (p=0.01), accurately identifying 92% of lesions, while it was negative in 4% and misleading in 4% of cases. Early postoperative biochemical remission was achieved in 88% of cases, while 84% remained in remission at follow-up.</p><p><strong>Conclusions: </strong>PCD-CT had a high rate of adenoma localization confirmed intraoperatively, even among MR-negative cases, potentially leading to high remission and gland preservation rates. Its role in the clinical workflow of preoperative evaluation for CD requires further investigation, but current evidence supports its value in lesion localization, especially in MR-negative disease.</p><p><strong>Abbreviations: </strong>CD= cushing disease; PCD= photon counting detector.</p>","PeriodicalId":93863,"journal":{"name":"AJNR. American journal of neuroradiology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJNR. American journal of neuroradiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3174/ajnr.A8893","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: MRI fails to localize a tumor in up to 40% of cases of ACTH dependent Cushing Disease (CD), impacting patient outcomes and creating uncertainty in the diagnosis. Photon-counting detector CT (PCD-CT) is a new CT technology with better imaging performance than conventional CT. PCD-CT is a novel imaging technique for CD, especially for MR-negative cases, however its application to CD remains unknown.

Materials and methods: We present a cohort of consecutive patients with a pre-operative PCD-CT undergoing transsphenoidal surgery for CD at a single institution from September 2023 to January 2025. All patients underwent gadolinium-enhanced pituitary MRI for baseline work-up and PCD-CT as part of their preoperative planning imaging. Both imaging modalities were used to localize the lesion and guide surgical planning. The accuracies of MRI and PCD-CT were based on confirmation of the lesion location by a combination of intraoperative visualization, pathologic confirmation, and postoperative biochemical remission, and were compared with each other via Fisher's exact test.

Results: Twenty-five patients with CD were included in this analysis. The cohort's median age was 50 years old, and 88% were female. At diagnosis, 88% had central obesity, 76% had hypertension, 48% had type II diabetes mellitus, and 20% had osteoporosis. Contrast-enhanced MRI accurately identified 56% of lesions, while it was negative in 24% and misleading in 20%. Dynamic contrast-enhanced PCD-CT was superior in localizing CD (p=0.01), accurately identifying 92% of lesions, while it was negative in 4% and misleading in 4% of cases. Early postoperative biochemical remission was achieved in 88% of cases, while 84% remained in remission at follow-up.

Conclusions: PCD-CT had a high rate of adenoma localization confirmed intraoperatively, even among MR-negative cases, potentially leading to high remission and gland preservation rates. Its role in the clinical workflow of preoperative evaluation for CD requires further investigation, but current evidence supports its value in lesion localization, especially in MR-negative disease.

Abbreviations: CD= cushing disease; PCD= photon counting detector.

垂体光子计数检测器CT对库欣病的诊断:术前病灶定位、术中发现和术后结果。
背景和目的:在高达40%的ACTH依赖性库欣病(CD)病例中,MRI不能定位肿瘤,影响患者的预后并造成诊断的不确定性。光子计数检测器CT (PCD-CT)是一种新型的CT技术,具有比传统CT更好的成像性能。PCD-CT是一种新的CD成像技术,特别是对mr阴性病例,但其在CD中的应用尚不清楚。材料和方法:我们提出了一个队列,从2023年9月到2025年1月,在同一家机构接受经蝶窦手术的连续术前PCD-CT患者。所有患者均接受垂体钆增强MRI作为基线检查和PCD-CT作为术前计划成像的一部分。两种成像方式用于定位病变和指导手术计划。MRI和PCD-CT的准确性基于术中可视化、病理证实和术后生化缓解相结合对病变位置的确认,并通过Fisher精确检验相互比较。结果:25例乳糜泻患者纳入本分析。该队列的中位年龄为50岁,88%为女性。诊断时,88%患有中心性肥胖,76%患有高血压,48%患有II型糖尿病,20%患有骨质疏松症。对比增强MRI准确识别56%的病变,24%为阴性,20%为误导。动态增强PCD-CT在CD定位方面具有优势(p=0.01), 92%的病变准确识别,4%的病变阴性,4%的病变误导。88%的患者术后早期生化缓解,84%的患者随访时仍处于缓解状态。结论:PCD-CT术中确认腺瘤定位的比例很高,即使在mr阴性的病例中也是如此,这可能导致高缓解率和腺体保存率。它在CD术前评估的临床工作流程中的作用有待进一步研究,但目前的证据支持它在病变定位方面的价值,特别是在mr阴性疾病中。缩写词:CD=库欣病;光子计数检测器。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信